Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Multiple Sclerosis l: Introduction

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Methods of Documentation VI: Case Management Model

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...

Nephrotic Syndrome III : Nursing Management

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis.

Cell death & disease·2018

Same author

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Neurology·2018

Same author

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Neurology·2018

Same author

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study.

Therapeutic advances in neurological disorders·2018

Same author

Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2018

Same author

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2018

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Evolving expectations around early management of multiple sclerosis.

Ralf Gold¹, Jerry S Wolinsky, Maria Pia Amato

¹Department of Neurology, St. Josef-Hospital/Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany.

Therapeutic Advances in Neurological Disorders

|December 24, 2010

Summary

Early treatment with interferon beta for clinically isolated syndrome (CIS) can delay multiple sclerosis progression and protect cognitive function. This intervention is crucial for optimizing long-term outcomes in neuroinflammatory diseases.

Keywords:

clinically isolated syndrome cognition disease-modifying treatments early treatment interferon beta multiple sclerosis

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

Area of Science:

Neuroimmunology
Clinical Neurology

Background:

Multiple sclerosis (MS) is a progressive central nervous system inflammatory disease.
Early intervention with disease-modifying treatments (DMTs) is recommended to optimize long-term outcomes.
Clinically isolated syndrome (CIS) may precede clinically definite MS, and cognitive impairment can be present early.

Purpose of the Study:

To evaluate the role of early interferon beta treatment in managing CIS.
To assess the impact of early interferon beta on disease progression and cognitive function.
To highlight the neuroprotective potential of interferon beta beyond its anti-inflammatory effects.

Main Methods:

Review of clinical trial data on early interferon beta treatment in CIS patients.
Analysis of studies investigating cognitive impairment in CIS and its prognostic relevance.
Examination of evidence for interferon beta's direct and indirect neuroprotective mechanisms.

Main Results:

Early interferon beta treatment significantly reduces the conversion rate from CIS to clinically definite MS.
Interferon beta may offer a protective effect on cognitive function in early stages of MS.
Long-term safety and efficacy of interferon beta are supported by over 15 years of clinical experience.

Conclusions:

Starting DMTs, such as interferon beta, early in the course of MS, even after CIS, is supported by evidence.
Early treatment can mitigate disease progression, preserve cognitive function, and potentially protect against neuronal damage.
Interferon beta demonstrates both anti-inflammatory and neuroprotective properties beneficial for MS management.